Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Academies’ Follow-up To Fink Report Calls For New Independent Advisory Body To Assess Biological Threats

This article was originally published in The Pink Sheet Daily

Executive Summary

The new advisory body would have a mission distinct from that of the recently formed National Science Advisory Board for Biosecurity.

You may also be interested in...



Leavitt Defends Bush’s Flu Pandemic Preparedness Plan To Senate

HHS will subsidize about 25% of states’ antiviral costs, leading senators to question whether preparedness in some states could suffer.

Rep. Castle Looks Ahead To September Stem Cell Clash

The representative remains resolute in the wake of scientific findings that could be used by some to undercut his Stem Cell Research Enhancement Act (HR 810/S 471).

Sen. Kerry Dismayed By Lack Of Congressional Action On HIV Vaccines

Congress has missed opportunities to offer significant support for HIV vaccine research, Sen. John Kerry (D-Mass.) said at a June 23 Foreign Relations Committee hearing on the topic of HIV vaccines. Both the Senate and the House have passed resolutions this year supporting the acceleration of HIV vaccine research. New estimates from the United Nations program on HIV/AIDS suggest that the developing world will need $15 bil. in 2006 to help reverse the spread of the disease.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel